Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

₹ 1,185 -0.27%
16 Jul - close price
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

One of the top five pharmaceutical companies in India.[1]

  • Market Cap 1,19,219 Cr.
  • Current Price 1,185
  • High / Low 1,203 / 564
  • Stock P/E 30.9
  • Book Value 197
  • Dividend Yield 0.25 %
  • ROCE 22.3 %
  • ROE 20.7 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 8.23% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
3,670 4,025 3,760 3,640 3,806 4,073 4,135 4,257 5,011 5,140 4,369 4,505 5,534
2,821 3,092 2,860 2,888 3,088 3,240 3,319 3,301 3,755 3,634 3,223 3,403 3,903
Operating Profit 850 933 900 752 718 833 815 956 1,256 1,505 1,146 1,102 1,630
OPM % 23% 23% 24% 21% 19% 20% 20% 22% 25% 29% 26% 24% 29%
-125 54 2,443 54 64 55 50 39 -566 21 53 60 160
Interest 23 27 30 31 38 34 35 33 28 18 9 20 35
Depreciation 175 183 177 177 185 181 182 182 179 180 184 195 205
Profit before tax 526 777 3,135 598 558 673 648 780 484 1,328 1,006 947 1,550
Tax % -39% 18% 4% 18% 20% 18% 21% 25% 28% 16% 22% 23% 21%
735 642 3,012 511 453 576 526 631 358 1,134 803 790 1,246
EPS in Rs 6.63 5.74 29.33 4.89 3.88 5.06 5.16 6.15 2.93 10.74 7.91 7.80 11.75
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
6,358 7,224 8,651 9,427 9,376 11,905 13,166 14,253 14,404 15,110 17,237 19,547
5,228 6,021 6,896 7,095 7,474 9,074 10,174 11,455 11,013 11,768 13,378 14,163
Operating Profit 1,130 1,203 1,756 2,332 1,902 2,831 2,991 2,798 3,391 3,342 3,860 5,384
OPM % 18% 17% 20% 25% 20% 24% 23% 20% 24% 22% 22% 28%
32 30 45 112 127 111 183 -264 -231 2,581 -422 293
Interest 169 90 68 53 45 91 194 342 159 127 130 81
Depreciation 185 201 287 292 373 539 599 696 670 713 723 764
Profit before tax 809 942 1,446 2,099 1,612 2,312 2,382 1,495 2,331 5,084 2,585 4,832
Tax % 15% 11% 18% 8% 8% 24% 22% 21% 8% 10% 23% 20%
690 836 1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,092 3,973
EPS in Rs 6.38 7.85 11.24 18.89 14.53 17.35 18.06 11.49 20.84 43.83 19.37 38.36
Dividend Payout % 24% 23% 21% 17% 22% 20% 19% 30% 17% 6% 31% 8%
Compounded Sales Growth
10 Years: 10%
5 Years: 8%
3 Years: 11%
TTM: 13%
Compounded Profit Growth
10 Years: 17%
5 Years: 17%
3 Years: 18%
TTM: 63%
Stock Price CAGR
10 Years: 19%
5 Years: 39%
3 Years: 23%
1 Year: 97%
Return on Equity
10 Years: 21%
5 Years: 20%
3 Years: 21%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 102 102 102 102 102 102 102 102 102 102 101 101
Reserves 2,842 3,337 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 17,415 19,729
2,918 2,700 2,651 2,442 5,207 5,407 7,899 7,986 4,608 4,221 1,195 804
1,512 1,847 2,144 2,208 2,937 3,632 4,945 5,115 6,165 6,421 6,851 8,201
Total Liabilities 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834
3,026 3,124 3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,188 11,521 12,368
CWIP 736 892 798 951 1,543 1,527 837 742 783 726 1,201 2,423
Investments 114 87 154 416 435 746 674 765 830 3,288 1,547 1,220
3,498 3,885 4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,294 12,822
Total Assets 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
603 903 994 1,894 1,312 919 1,282 2,932 3,294 2,104 2,689 3,228
-682 -438 -465 -860 -2,872 -974 -3,977 -1,004 -837 -1,018 1,542 -1,492
286 -529 -351 -935 2,316 52 1,885 -1,528 -2,548 -868 -4,400 -1,810
Net Cash Flow 207 -64 178 99 756 -3 -811 399 -90 219 -170 -75

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 55 57 67 68 89 98 110 94 79 81 94 97
Inventory Days 191 184 175 158 193 211 208 207 246 245 197 202
Days Payable 103 123 125 154 165 167 149 152 168 141 123 125
Cash Conversion Cycle 142 119 118 71 116 142 169 149 158 185 168 175
Working Capital Days 63 46 56 46 62 95 99 79 95 112 95 103
ROCE % 18% 17% 23% 28% 16% 18% 15% 11% 14% 13% 15% 22%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
74.88% 74.88% 74.88% 74.88% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98%
4.11% 3.79% 2.53% 2.86% 2.61% 2.52% 3.42% 4.04% 4.85% 4.99% 5.72% 5.59%
11.25% 11.80% 12.83% 11.94% 12.86% 13.61% 13.51% 13.44% 13.01% 12.96% 12.55% 12.56%
0.07% 0.07% 0.08% 0.08% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07%
9.69% 9.46% 9.69% 10.24% 9.47% 8.81% 8.01% 7.47% 7.07% 6.99% 6.66% 6.81%
No. of Shareholders 3,51,5953,70,9314,08,0174,55,6244,08,2313,70,3963,38,5703,11,7642,97,9533,06,4952,94,3243,36,309

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls